• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Aldosterone antagonist therapy linked to reduced mortality following STEMI without heart failure

byJames EnglandandAnees Daud
May 30, 2018
in Cardiology, Emergency, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this meta-analysis of available randomized clinical trials, use of aldosterone antagonist therapy in patients with preserved ejection fraction following ST-elevation myocardial infarction (STEMI) was associated with reduction in overall mortality.

2. Use of aldosterone agonist was linked to a small increase in serum potassium and no overall difference in serum creatinine levels.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Aldosterone antagonists (AAs) following primary acute management of STEMI has been demonstrated to reduce ventricular remodeling following ischemic insult and improve mortality in patients with reduced ejection fraction. The utility of AA therapy in patients with preserved ejection fraction has not been definitively demonstrated, though a number of trials have attempted to look at the role of AA therapy following myocardial infarction (MI). The current study is a meta-analysis of available randomized clinical trials (RCTs) that evaluated the role of AA therapy following STEMI in patients with preserved ejection fraction. The study found that AA use was linked to an overall improved mortality but similar rates of heart failure, recurrent MI, and arrhythmia compared to placebo. There was also a small increase in potassium level but no significant reduction in creatinine clearance.

The main strength of the study is the inclusion of high-quality trials with a large number of combined patients. The lack of patient specific data, and variation in primary MI management, type of AA therapy, and use of other agents may lead to bias in the results.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Mineralocorticoid receptor antagonists in patients with acute myocardial infarction — A systematic review and meta-analysis of randomized trials

RELATED REPORTS

Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy

#VisualAbstract: Routine invasive strategy not associated with improved outcomes in older adults with frailty and non-ST segment elevation acute myocardial infarction

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

In-Depth [ systematic review and meta-analysis]: This study included RCTs which evaluated the effects of AAs for patients over the age of 18 with STEMI and either no heart failure, or measured ejection fraction >40%.  Studies were excluded if they did not report the outcomes under investigation for this study, or if patients had ejection fractions less than 40%. The main outcomes were mortality, new heart failure, recurrent MI, ventricular arrhythmia, changes in serum potassium, and creatinine level.

A total of 10 trials were included encompassing 4147 patients and the following AAs: spironolactone, eplerenone, and canrenoate. Use of AA was linked with lower mortality (2.4%vs 3.9%; odds ratio [OR], 0.62; 95%CI, 0.42-0.91; p = 0.01), but no difference in new heart failure (OR 0.82; 95%CI, 0.56-1.20; p = 0.31), recurrent MI (OR 1.03; 95%CI, 0.57-1.86; p = 0.91), or ventricular arrhythmia (OR 0.76; 95%CI, 0.45-1.31; p = 0.33). There was an observed increase in serum potassium of 0.07 mEq/l (p = 0.02), but no change in serum creatinine (p = 0.13).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: myocardial infarctionspironolactone
Previous Post

Physicians should look for misuse patterns that lead to overdose before prescribing opioids

Next Post

Prediction tool helps tailor lung cancer screening to patient benefit and preferences

RelatedReports

Patient Basics: Thrombotic Stroke
Imaging and Intervention

Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy

March 24, 2023
StudyGraphics

#VisualAbstract: Routine invasive strategy not associated with improved outcomes in older adults with frailty and non-ST segment elevation acute myocardial infarction

March 18, 2023
Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease
Cardiology

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

December 6, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Personalized cooler dialysate does not reduce cardiovascular events for hemodialysis patients

November 23, 2022
Next Post
Lessons from real-world implementation of lung cancer screening

Prediction tool helps tailor lung cancer screening to patient benefit and preferences

ECMO for severe ARDS does not improve mortality

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

MRI pattern selects patients with unknown stroke time who benefit from thrombolysis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Metformin use may decrease risk of osteoarthritis development
  • Intensive blood pressure lowering by non-physician healthcare providers significantly reduces the risk of cardiovascular disease
  • Expectant management of patent ductus arteriosus noninferior to early ibuprofen use
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options